Increasing evidence has revealed that EZH2 has oncogenic properties, as an increased expression of EZH2 augments proliferation and invasion of cancer cells [92–94], while depletion leads to a decline in cell proliferation, increased apoptosis, and inhibition of metastatic tumor growth in vivo [95, 96]. This evidence concerns the gene EZH2 and metastatic neoplasm.